TOP TEN perturbations for 39179_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39179_at
Selected probe(set): 211743_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39179_at (211743_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):7.3696804Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
B-CLL study 5 / normal bone marrow sample
Relative Expression (log2-ratio):-6.4825993Number of Samples:441 / 74
| Experimental | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-4.621192Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-4.5921154Number of Samples:36 / 74
| Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
| Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-4.2867384Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-4.1083136Number of Samples:232 / 74
| Experimental | c-ALL/pre-B-ALL study 1 |
| Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
B-ALL study 1 (hyperdiploid) / normal bone marrow sample
Relative Expression (log2-ratio):-4.0864315Number of Samples:40 / 74
| Experimental | B-ALL study 1 (hyperdiploid) |
| Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.9411535Number of Samples:70 / 74
| Experimental | precursor-B-ALL study 1 (t(11q23)) |
| Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.788806Number of Samples:58 / 74
| Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
| Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
T-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-3.7302847Number of Samples:174 / 74
| Experimental | T-ALL study 1 |
| Bone marrow samples of patients with T-ALL. | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
Organism: Homo sapiens
Gene: 39179_at
Selected probe(set): 211743_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39179_at (211743_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):7.3696804Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
B-CLL study 5 / normal bone marrow sample
Relative Expression (log2-ratio):-6.4825993Number of Samples:441 / 74
| Experimental | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-4.621192Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-4.5921154Number of Samples:36 / 74
| Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
| Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-4.2867384Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-4.1083136Number of Samples:232 / 74
| Experimental | c-ALL/pre-B-ALL study 1 |
| Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
B-ALL study 1 (hyperdiploid) / normal bone marrow sample
Relative Expression (log2-ratio):-4.0864315Number of Samples:40 / 74
| Experimental | B-ALL study 1 (hyperdiploid) |
| Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.9411535Number of Samples:70 / 74
| Experimental | precursor-B-ALL study 1 (t(11q23)) |
| Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.788806Number of Samples:58 / 74
| Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
| Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
T-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-3.7302847Number of Samples:174 / 74
| Experimental | T-ALL study 1 |
| Bone marrow samples of patients with T-ALL. | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |